27 Apr Tomosynthesis is Mammography Made Better
MedicalResearch.com Interview with:
Elizabeth A. Rafferty, MD
Department of Radiology,
Massachusetts General Hospital, Boston
Now with L&M Radiology, West Acton,
MedicalResearch.com: What is the background for this study? What are the main findings?
Dr. Rafferty: Breast tomosynthesis has been approved for mammographic screening in the United States for just over 5 years, and many single center studies have demonstrated its improved performance for screening outcomes over digital mammography alone. Our previously published multi-center analysis, (JAMA 2014;311(24), the largest study on this topic to date, demonstrated significantly improved cancer detection and reduced recall rates for women undergoing tomosynthesis compared with digital mammography alone. In the current issue of JAMA we evaluate the differential screening performance after implementation of breast tomosynthesis as a function of breast density.
While tomosynthesis continues to be increasingly available, questions remained about which women should be imaged with this technique. In particular, does this technology offer additional benefit for all women, or only for women with dense breasts. The size of the database compiled by the centers participating in this study allowed us to evaluate this important question.
The most critical finding of our study was that the use of tomosynthesis for breast cancer screening significantly improved invasive cancer detection rates while simultaneously significantly reducing recall rates both for women with dense and non-dense breast tissue. Having said that, the magnitude of the benefit was largest for women with heterogeneously dense breast tissue; for this population, tomosynthesis increased the detection of invasive cancers by 50% while simultaneously reducing the recall rate by 14%.
MedicalResearch.com: What should clinicians and patients take away from your report?
Dr. Rafferty: Clinicians and patients should know that the data is clear that screening mammography saves lives, and over the years patient outcomes have improved as we improved our imaging techniques. Tomosynthesis now represents the state of the art in mammography technology. As a clinician recommending a mammogram for your patient or as a woman choosing a mammogram for yourself, optimally you would want the mammogram with the best performance–today that is breast tomosynthesis. Our paper published this week in JAMA adds compelling evidence that the improved performance outcomes achieved with tomosynthesis are seen in both women with dense and non-dense breast tissue.
MedicalResearch.com: What recommendations do you have for future research as a result of this study?
Dr. Rafferty: The addition of tomosynthesis significantly improves mammographic performance, most substantially for women with dense breasts. Future research could focus on whether supplemental screening with other modalities such as ultrasound or MRI offer additional gains, and if so, for what specific populations. This information would allow us to better guide women in their decisions regarding the optimal screening regimen for them.
MedicalResearch.com: Is there anything else you would like to add?
Dr. Rafferty: Mammography saves lives; it is the only breast cancer screening tool that has met that standard.
Tomosynthesis is mammography made better. It is my belief that as tomosynthesis becomes more widely adopted we will see even further gains in our fight against breast cancer
MedicalResearch.com: Thank you for your contribution to the MedicalResearch.com community.
Elizabeth A. Rafferty, Melissa A. Durand, Emily F. Conant, Debra Somers Copit, Sarah M. Friedewald, Donna M. Plecha, Dave P. Miller. Breast Cancer Screening Using Tomosynthesis and Digital Mammography in Dense and Nondense Breasts. JAMA, 2016; 315 (16): 1784 DOI:10.1001/jama.2016.1708
Note: Content is Not intended as medical advice. Please consult your health care provider regarding your specific medical condition and questions.
Last Updated on April 27, 2016 by Marie Benz MD FAAD